The Swiss HIV Cohort Study - A link between clinical research and patient care;Die Schweizerische HIV-Kohortenstudie - Verbindung zwischen klinischer Forschung und ärztlicher Praxis

Therapeutische Umschau

Volumn 55, Issue 5, 1998, Pages 329-334

  Opravil, M ^a   Rickenbach, M ^b   Ledergerber, B ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PROSPECTIVE STUDY; RESEARCH; RISK FACTOR; SWITZERLAND;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RESEARCH; RISK FACTORS; SWITZERLAND;

EID: 0032060444     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kinloch-de Loes S., de Saussure P., Saurat J. H., Stalder H., Hirschel B., Perrin L. H.: Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin. Infect Dis. 17, 59, 1993.
2. Aids und HIV in der Schweiz. Epidemiologische Situation Ende 1996. Bundesamt für Gesundheitswesen, August 1997.
3. Von Overbeck J. et al.: Survival in HIV infection: Do gender and manner of transmission matter? AIDS 8, 1307. 1994.
4. Egger M. et al.: Marked decrease in progression and mortality of HIV infection in Switzerland. BMJ 315, 1194, 1997.
5. Lundgren J. D. et al.: Survival differences in European Patients with AIDS 1979-1989. BMJ 308, 1068, 1994.
6. Mocroft A. J. et al.: Survival of AIDS patients according to type of AIDS defining event. Int. J. Epidemiol. 26, 400, 1997.
7. Lundgren J. D. et al.: Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16, 153, 1997.
8. Hirschel B. et al.: A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N. Engl. J. Med. 342, 1079, 1991.
9. Opravil M. et al.: Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 20, 531, 1995.
10. Delta Coordinating Committee. Delta: a randomised double-bund controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348, 283, 1996.
11. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 349, 1413, 1997.
12. Kinloch-de Loes S. et al.: Zidovudine versus placebo in primary HIV infection: a randomized study. N. Engl. J. Med. 333, 408, 1995.
13. Schacker T., Collier A. C., Hughes J., Shea T., Corey L.: Clinical and epidemiologic features of primary HIV infection. Ann. Intern. Med. 125, 257, 1996.
14. Van Delden C. et al.: Reasons for failure or prevention of Toxoplasma encephalitis. AIDS 10, 509, 1996.